194 related articles for article (PubMed ID: 23360641)
1. Antiproliferative effect of pHLIP-amanitin.
Moshnikova A; Moshnikova V; Andreev OA; Reshetnyak YK
Biochemistry; 2013 Feb; 52(7):1171-8. PubMed ID: 23360641
[TBL] [Abstract][Full Text] [Related]
2. Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors.
Wyatt LC; Moshnikova A; Crawford T; Engelman DM; Andreev OA; Reshetnyak YK
Proc Natl Acad Sci U S A; 2018 Mar; 115(12):E2811-E2818. PubMed ID: 29507241
[TBL] [Abstract][Full Text] [Related]
3. Tuning a polar molecule for selective cytoplasmic delivery by a pH (Low) insertion peptide.
Wijesinghe D; Engelman DM; Andreev OA; Reshetnyak YK
Biochemistry; 2011 Nov; 50(47):10215-22. PubMed ID: 22029270
[TBL] [Abstract][Full Text] [Related]
4. pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation.
An M; Wijesinghe D; Andreev OA; Reshetnyak YK; Engelman DM
Proc Natl Acad Sci U S A; 2010 Nov; 107(47):20246-50. PubMed ID: 21048084
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cancer cell proliferation and breast tumor targeting of pHLIP-monomethyl auristatin E conjugates.
Burns KE; Robinson MK; Thévenin D
Mol Pharm; 2015 Apr; 12(4):1250-8. PubMed ID: 25741818
[TBL] [Abstract][Full Text] [Related]
6. pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents.
Andreev OA; Engelman DM; Reshetnyak YK
Mol Membr Biol; 2010 Oct; 27(7):341-52. PubMed ID: 20939768
[TBL] [Abstract][Full Text] [Related]
7. Determination of the Membrane Translocation pK of the pH-Low Insertion Peptide.
Scott HL; Westerfield JM; Barrera FN
Biophys J; 2017 Aug; 113(4):869-879. PubMed ID: 28834723
[TBL] [Abstract][Full Text] [Related]
8. Noncanonical amino acids to improve the pH response of pHLIP insertion at tumor acidity.
Onyango JO; Chung MS; Eng CH; Klees LM; Langenbacher R; Yao L; An M
Angew Chem Int Ed Engl; 2015 Mar; 54(12):3658-3663. PubMed ID: 25650762
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.
Svoronos AA; Bahal R; Pereira MC; Barrera FN; Deacon JC; Bosenberg M; DiMaio D; Glazer PM; Engelman DM
Mol Pharm; 2020 Feb; 17(2):461-471. PubMed ID: 31855437
[TBL] [Abstract][Full Text] [Related]
10. Targeting Bladder Urothelial Carcinoma with pHLIP-ICG and Inhibition of Urothelial Cancer Cell Proliferation by pHLIP-amanitin.
Moshnikova A; Golijanin B; Amin A; Doyle J; Kott O; Gershman B; DuPont M; Li Y; Lu X; Engelman DM; Andreev OA; Reshetnyak YK; Golijanin D
Front Urol; 2022; 2():. PubMed ID: 36439552
[TBL] [Abstract][Full Text] [Related]
11. Energetics of peptide (pHLIP) binding to and folding across a lipid bilayer membrane.
Reshetnyak YK; Andreev OA; Segala M; Markin VS; Engelman DM
Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15340-5. PubMed ID: 18829441
[TBL] [Abstract][Full Text] [Related]
12. pHLIP-mediated translocation of membrane-impermeable molecules into cells.
Thévenin D; An M; Engelman DM
Chem Biol; 2009 Jul; 16(7):754-62. PubMed ID: 19635412
[TBL] [Abstract][Full Text] [Related]
13. pH-dependent thermodynamic intermediates of pHLIP membrane insertion determined by solid-state NMR spectroscopy.
Otieno SA; Hanz SZ; Chakravorty B; Zhang A; Klees LM; An M; Qiang W
Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12194-12199. PubMed ID: 30442664
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the pHLIP transmembrane helix insertion pathway.
Karabadzhak AG; Weerakkody D; Wijesinghe D; Thakur MS; Engelman DM; Andreev OA; Markin VS; Reshetnyak YK
Biophys J; 2012 Apr; 102(8):1846-55. PubMed ID: 22768940
[TBL] [Abstract][Full Text] [Related]
15. pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
Yu M; Chen Y; Wang Z; Ding X
Breast Cancer Res Treat; 2020 Apr; 180(2):379-384. PubMed ID: 32034579
[TBL] [Abstract][Full Text] [Related]
16. pHLIP®-mediated delivery of PEGylated liposomes to cancer cells.
Yao L; Daniels J; Wijesinghe D; Andreev OA; Reshetnyak YK
J Control Release; 2013 May; 167(3):228-37. PubMed ID: 23416366
[TBL] [Abstract][Full Text] [Related]
17. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
18. Tuning the insertion properties of pHLIP.
Musial-Siwek M; Karabadzhak A; Andreev OA; Reshetnyak YK; Engelman DM
Biochim Biophys Acta; 2010 Jun; 1798(6):1041-6. PubMed ID: 19766589
[TBL] [Abstract][Full Text] [Related]
19. Cellular delivery of doxorubicin mediated by disulfide reduction of a peptide-dendrimer bioconjugate.
Burns KE; Delehanty JB
Int J Pharm; 2018 Jul; 545(1-2):64-73. PubMed ID: 29709616
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to pH-Responsive targeted cancer Therapy: Inhibition of FaDu cancer cell proliferation with a pH low insertion Peptide-Conjugated DGAT1 inhibitor.
Deskeuvre M; Lan J; Messens J; Riant O; Feron O; Frédérick R
Int J Pharm; 2024 May; 657():124132. PubMed ID: 38641019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
